In the field of pharmaceuticals, the term 'polymorphism' refers to the existence of a single substance in two or more crystalline forms. These different forms can vary widely in their efficacy, bioavailability and even toxicity. An EU-funded project is working to develop a method for directing polymorphism in pharmaceutical compounds, thus promising better drug treatments for patients everywhere.
EU-funded researchers have discovered an important new mechanism by which cells flag and repair damage to their DNA - an unexpected finding that could improve the treatment of diseases such as cancer.
An organic molecule composed of simple sugars could become a potent weapon in the fight against rising antibiotic resistance, according to EU-funded researchers who have developed a novel, targeted drug-delivery technique to treat deadly tuberculosis and other lethal pathogens.
CT scans have revolutionised the fight against human illness by creating three-dimensional images of the body's inner workings. Such scans, however, can deliver high doses of radiation. Now EU-funded researchers have built special cameras that limit radiation while delivering images vital for patient health.
A special capsule that shields transplanted insulin-producing cells from a recipient's immune system represents a cost-effective improvement in treatment for diabetes patients. The biomaterials developed and put through preclinical trials by an EU-funded project could also have other applications, such as repairing organs.
An EU-funded project is supporting innovative nanotechnology research, with a platform for improved cancer monitoring among its successes. This promises earlier and more cost-effective detection of cancers and can guide individualised therapeutic approaches.
Finnish firm Mobidiag has received a EUR 25-million European Investment Bank (EIB) loan to accelerate development and commercialisation of its fast, life-saving tests for small laboratories. The support, provided under the European Fund for Strategic Investments, adds to a previous EUR 15 million EIB loan extended under the InnovFin Infectious Diseases Finance Facility under the EU's Horizon 2020 programme.
People suffering from Type 1 diabetes are set to benefit from an innovative therapy being developed in an EU-funded project that promises to restore the body's ability to regulate blood sugar via a small bioengineered implant.
Multifunctional nanoparticles being developed by EU-funded researchers are set to revolutionise treatments for complex bone diseases, enabling novel therapies for hundreds of millions of people worldwide suffering from bone cancer, bacterial bone infections and osteoporosis.
EU-funded biotechnology researchers have developed a novel treatment for atherosclerosis, the narrowing and hardening of arteries that is the leading underlying cause of death and disability in Europe.
